Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program [Original Articles]
Conclusions—
In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research
More News: Abciximab | Angioplasty | Bleeding | Cardiology | Cardiovascular | Coronary Angioplasty | Dialysis | Eptifibatide | Heart | Integrilin | Percutaneous Coronary Intervention | Stroke | Thrombocytopenia